In this video, Fool.com health care analysts David Williamson and Max Macaluso discuss Gilead, Amarin, and Cyclacel's intraday pops of more than 5%. One reported excellent earnings, another is subject to buyout rumors, and a third continues its recent winning streak. Watch and find out what this means for these stocks, their competitors, and investors.
The biotech space can make or break investors overnight, and while Amarin might not disappear into thin air, the success of its new triglyceride-lowering drug is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with top Fool.com analyst Max Macaluso's premium research report. Click here now to keep reading.